Takashi Kei Kishimoto - Net Worth and Insider Trading
Takashi Kei Kishimoto Net Worth
The estimated net worth of Takashi Kei Kishimoto is at least $217,499 dollars as of 2024-11-29. Takashi Kei Kishimoto is the Chief Scientific Officer of Cartesian Therapeutics Inc and owns about 12,144 shares of Cartesian Therapeutics Inc (RNAC) stock worth over $217,499. Details can be seen in Takashi Kei Kishimoto's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Takashi Kei Kishimoto has not made any transactions after 2023-01-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Takashi Kei Kishimoto
Takashi Kei Kishimoto Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Takashi Kei Kishimoto owns 1 companies in total, including Cartesian Therapeutics Inc (RNAC) .
Click here to see the complete history of Takashi Kei Kishimoto’s form 4 insider trades.
Insider Ownership Summary of Takashi Kei Kishimoto
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RNAC | Cartesian Therapeutics Inc | 2023-01-05 | Chief Scientific Officer |
Takashi Kei Kishimoto Latest Holdings Summary
Takashi Kei Kishimoto currently owns a total of 1 stock. Takashi Kei Kishimoto owns 12,144 shares of Cartesian Therapeutics Inc (RNAC) as of January 5, 2023, with a value of $217,499.
Latest Holdings of Takashi Kei Kishimoto
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RNAC | Cartesian Therapeutics Inc | 2023-01-05 | 12,144 | 17.91 | 217,499 |
Holding Weightings of Takashi Kei Kishimoto
Takashi Kei Kishimoto Form 4 Trading Tracker
According to the SEC Form 4 filings, Takashi Kei Kishimoto has made a total of 3 transactions in Cartesian Therapeutics Inc (RNAC) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Cartesian Therapeutics Inc is the sale of 326 shares on January 5, 2023, which brought Takashi Kei Kishimoto around $11,056.
Insider Trading History of Takashi Kei Kishimoto
- 1
Takashi Kei Kishimoto Trading Performance
Takashi Kei Kishimoto Ownership Network
Takashi Kei Kishimoto Owned Company Details
What does Cartesian Therapeutics Inc do?
Who are the key executives at Cartesian Therapeutics Inc?
Takashi Kei Kishimoto is the Chief Scientific Officer of Cartesian Therapeutics Inc. Other key executives at Cartesian Therapeutics Inc include Chief Medical Officer Peter G Traber , director & President & CEO Carsten Brunn , and COO and SVP & R&D Lloyd P. Johnston .
Cartesian Therapeutics Inc (RNAC) Insider Trades Summary
Over the past 18 months, Takashi Kei Kishimoto made no insider transaction in Cartesian Therapeutics Inc (RNAC). Other recent insider transactions involving Cartesian Therapeutics Inc (RNAC) include a net purchase of 1,868,993 shares made by Timothy A Springer , a net sale of 52,115 shares made by , and a net purchase of 7,500 shares made by Timothy C Barabe .
In summary, during the past 3 months, insiders sold 228,172 shares of Cartesian Therapeutics Inc (RNAC) in total and bought 637,661 shares, with a net purchase of 409,489 shares. During the past 18 months, 228,293 shares of Cartesian Therapeutics Inc (RNAC) were sold and 693,954 shares were bought by its insiders, resulting in a net purchase of 465,661 shares.
Cartesian Therapeutics Inc (RNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cartesian Therapeutics Inc Insider Transactions
Takashi Kei Kishimoto Mailing Address
Above is the net worth, insider trading, and ownership report for Takashi Kei Kishimoto. You might contact Takashi Kei Kishimoto via mailing address: 480 Arsenal St., Building One, Watertown Ma 02472.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
